Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
β3-integrin–deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival
Kairbaan M. Hodivala-Dilke, … , Steven Teitelbaum, Richard O. Hynes
Kairbaan M. Hodivala-Dilke, … , Steven Teitelbaum, Richard O. Hynes
Published January 15, 1999
Citation Information: J Clin Invest. 1999;103(2):229-238. https://doi.org/10.1172/JCI5487.
View: Text | PDF
Article

β3-integrin–deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival

  • Text
  • PDF
Abstract

β3 integrins have been implicated in a wide variety of functions, including platelet aggregation and thrombosis (αIIbβ3) and implantation, placentation, angiogenesis, bone remodeling, and tumor progression (αvβ3). The human bleeding disorder Glanzmann thrombasthenia (GT) can result from defects in the genes for either the αIIb or the β3 subunit. In order to develop a mouse model of this disease and to further studies of hemostasis, thrombosis, and other suggested roles of β3 integrins, we have generated a strain of β3-null mice. The mice are viable and fertile, and show all the cardinal features of GT (defects in platelet aggregation and clot retraction, prolonged bleeding times, and cutaneous and gastrointestinal bleeding). Implantation appears to be unaffected, but placental defects do occur and lead to fetal mortality. Postnatal hemorrhage leads to anemia and reduced survival. These mice will allow analyses of the other suggested functions of β3 integrins and we report that postnatal neovascularization of the retina appears to be β3-integrin–independent, contrary to expectations from inhibition experiments.

Authors

Kairbaan M. Hodivala-Dilke, Kevin P. McHugh, Dimitrios A. Tsakiris, Helen Rayburn, Denise Crowley, Mollie Ullman-Culleré, F. Patrick Ross, Barry S. Coller, Steven Teitelbaum, Richard O. Hynes

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Targeting strategy, Southern blots and PCR analysis of ES cells and mice...
Targeting strategy, Southern blots and PCR analysis of ES cells and mice lacking the β3-integrin gene. (a) Structure of β3 targeting construct, wild-type β3 allele and targeted β3 allele. Exons are indicated as black boxes. The 1.7 kb pgk-neomycin-resistance cassette replaces a 1.4 kb HindIII fragment of the β3-gene including exons I and II. Pgk-thymidine kinase genes were used for negative selection. (b) Southern blot analysis of EcoRI, BstEII and NcoI-digested genomic DNA from a representative targeted clone (111). Probe A lay 5′ of the targeting construct and probe B lay inside it (a). (c) PCR analysis of wild-type, heterozygous and β3-null tail DNA used to screen offspring. Primer locations are indicated by half arrows in A and give products of 446 bp with primers 1 and 3 (wild-type) or 538 bp with primers 1 and 2 (mutant).

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts